Recurrent Ovarian Carcinoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
O
Active, not recruiting
  • BRCA1 Gene Mutation
  • +9 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-04-05
Apr 5, 2022
S
Active, not recruiting
  • Advanced Solid Tumors
  • +4 more
  • Phoenix, Arizona
  • +15 more
2022-04-04
Apr 4, 2022
N
Suspended
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +25 more
  • Pegylated Liposomal Doxorubicin Hydrochloride
  • Peposertib
  • Aurora, Colorado
  • +7 more
2022-04-05
Apr 5, 2022
N
Recruiting
  • Quality of Life
  • +2 more
  • Trabectidin (Yondelis)
  • Aachen, Germany
  • +32 more
2022-04-05
Apr 5, 2022
N
Recruiting
  • Recurrent Endometrial Endometrioid Adenocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +569 more
2022-04-05
Apr 5, 2022
N
Active, not recruiting
  • Fallopian Tube High Grade Serous Adenocarcinoma
  • +18 more
  • Anchorage, Alaska
  • +928 more
2022-04-05
Apr 5, 2022
N
Active, not recruiting
  • Metastatic Fallopian Tube Carcinoma
  • +11 more
  • Phoenix, Arizona
  • +13 more
2022-04-05
Apr 5, 2022
N
Active, not recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +7 more
  • Cediranib Maleate
  • +2 more
  • Phoenix, Arizona
  • +19 more
2022-04-05
Apr 5, 2022
N
Recruiting
  • Advanced Differentiated Thyroid Gland Carcinoma
  • +102 more
  • Cabozantinib S-malate
  • Nivolumab
  • Chicago, Illinois
  • +2 more
2022-04-05
Apr 5, 2022
R
Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
2022-04-04
Apr 4, 2022
L
Recruiting
  • Recurrent Ovarian Carcinoma
  • +7 more
  • Niraparib plus anlotinib
  • Beijing, Beijing, China
    Lei Li
2022-03-27
Mar 27, 2022
W
Recruiting
  • Solid Tumor, Adult
  • +27 more
  • Blood draws
  • +2 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
2022-04-04
Apr 4, 2022
L
Recruiting
  • Ovarian Carcinoma
  • +6 more
  • Albumin-bound paclitaxel and bevacizumab
  • Beijing, Beijing, China
    Lei Li
2022-03-26
Mar 26, 2022
N
Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Tucson, Arizona
  • +16 more
2022-04-01
Apr 1, 2022
N
Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
2022-03-10
Mar 10, 2022
M
Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
2022-03-09
Mar 9, 2022
U
Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-10
Mar 10, 2022
M
Active, not recruiting
  • Ovarian Serous Tumor
  • Recurrent Ovarian Carcinoma
  • Rochester, Minnesota
    Mayo Clinic
2022-03-22
Mar 22, 2022
N
Active, not recruiting
  • Ovarian Serous Tumor
  • +3 more
  • Phoenix, Arizona
  • +16 more
2022-03-23
Mar 23, 2022
M
Recruiting
  • Malignant Peritoneal Neoplasm
  • +33 more
  • Ipilimumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-08
Mar 8, 2022
R
Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +10 more
  • Bevacizumab
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2022-03-14
Mar 14, 2022